Flagship debuts Laronde to develop RNA-based meds that could turn cells into protein factories

Antibodies and other protein therapeutics can treat a wide range of diseases, but they come with various challenges that have limited their reach.

“They’re complex and expensive to make and complex to administer,” said Diego Miralles, M.D., a CEO-partner at Flagship Pioneering and CEO of its latest company, Laronde. What’s more, some treatments must be injected frequently because of their short half-lives, which can be a pain—literally—for patients.